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Introduction
A primary pulmonary invasive mucinous adenocarcinoma 
(IMA) is an adenocarcinoma variant according to the current 
World Health Organization (WHO) classification of lung 
tumors (1). IMAs are less prevalent than are invasive non-
mucinous adenocarcinomas (INMAs), accounting for 
approximately 5% of lung adenocarcinomas (2). IMAs have 
clinical, radiological, pathological, and genetic characteristics 
distinct from those of INMAs. In this article, we review the 
recently reported genetic and clinical characteristics as well as 
the general features of IMA of the lung.
Histopathology and immunohistochemical 
features of IMAs
By definition, IMAs consist of goblet and/or columnar 
tumor cells containing intracytoplasmic mucin (Figure 1), 
which are rarely observed in other lung adenocarcinomas 
(1,2). Because cytologic atypia is usually inconspicuous 
or absent in IMAs, definitive diagnosis of malignancy via 
biopsy is frequently challenging. In transbronchial biopsy, 
accurate targeting could be limited since most IMAs 
are located in the periphery of lower lobes. Moreover, 
submucosal mucinous glands of bronchial tissue and the 
tumor cells of IMA could mimic each other because of 
bland-looking cytomorphology and intracytoplasmic 
mucin. Percutaneous computer tomography (CT)-guided 
lung biopsy appears to be more effective way to obtain 
the diagnostic tissue, however biopsied specimen could be 
composed of acellular mucin pool only since the alveolar 
spaces at the tumor periphery are often filled with mucin, 
which may correspond to the lobar pneumonia-like area 
on the chest CT image. Even if tumor cells are included 
in the specimen, a small amount of mucinous cells with 
bland morphology could be insufficient to make a definitive 
diagnosis of malignancy. 
IMAs may show the same heterogeneous mixture of 
lepidic, acinar, papillary, micropapillary, and solid growth 
patterns as do INMAs (2). However, a lepidic growth 
pattern with microscopic skip lesions is a characteristic 
feature of IMAs, which is why they were formerly termed 
mucinous bronchioloalveolar carcinomas. Mixed invasive 
mucinous and non-mucinous adenocarcinomas, which are 
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currently classified as a subcategory of IMAs by the WHO, 
have the histomorphologic features of both IMAs and 
INMAs (1). IMAs sometimes show depleted cytoplasmic 
mucin and aggravated cytologic atypia in areas of stromal 
invasion; thus, the non-mucinous components in the mixed 
tumors presumably arise from high-grade transformation 
of pre-existing mucinous components. However, further 
discussion and investigation are still required. 
Colloid adenocarcinomas, in which abundant mucin 
pools replace air spaces, are also variants of lung 
adenocarcinomas (1). They differ from IMAs in two 
aspects: the mucin pools replace the underlying alveolar 
architecture, and scattered clusters of mucinous tumor cells 
are present (1). When diagnosing IMAs, the emphasis is 
made on intracellular mucin rather than extracellular mucin.
By immunohistochemistry,  most  IMAs express 
cytokeratin 7 (~88%) and cytokeratin 20 (~54%) (3-6). 
Expression rates of thyroid transcription factor-1 (TTF-1) 
and napsin A are variable in IMA but less than INMA, 
reported as approximately 40% and up to 33%, respectively 
(6,7). These findings support the premise that IMAs and 
INMAs have different cellular lineages. Previous studies 
categorized adenocarcinomas as terminal respiratory unit 
(TRU) type and non-TRU type, and IMAs are usually 
considered non-TRU type (8,9). 
IMAs were recently shown to selectively express 
hepatocyte nuclear factor 4α (HNF4α) (10,11), a transcription 
factor present in normal and malignant gastrointestinal 
mucosa (12). Such selective expression could discriminate 
IMAs from other mucin-producing adenocarcinomas 
such as those harboring EGFR or ALK mutations (11,13). 
A subset of adenocarcinomas with ALK rearrangements 
extensively produces extracellular mucin along with 
intracytoplasmic mucin, as do IMAs. However, because 
these adenocarcinomas differ from IMAs in terms 
of  mutational  status and consequently treatment 
strategies, accurate diagnosis is important and requires a 
comprehensive understanding of the genetic and histologic 
features including immunohistochemical profiles and 
cytomorphology (13). 
Genetic alterations and expression profiles
In addition to their striking histologic features, IMAs also 
have a distinct molecular signature. Recent high throughput 
analyses revealed several genetic abnormalities in IMAs 
including KRAS, BRAF, ERBB2, and PIK3CA mutations 
and NRG1,  BRAF,  NTRK1,  ALK ,  RET ,  and ERBB4 
rearrangements (14,15). KRAS mutations are the most 
frequent oncogenic driver mutations in IMAs (up to 86%) 
(14,15). However, IMAs and INMAs have different types 
of KRAS mutations: the most common types are G12D 
and G12V in IMAs and G12C in INMAs (15). G12D and 
G12V are most common in colorectal and pancreatobiliary 
carcinomas, suggesting that IMA of lung may be biologically 
more similar to pancreatobiliary and intestinal tract cancers. 
Although common in INMAs, EGFR mutations are very 
rare in IMAs (only 0–5%) (Figure 2) (14-17). 
NRG1  fusions have been recently identif ied in 
IMAs, with an estimated frequency of 7–27% (Figure 2) 
(14,18,19). The fusion partners for NRG1 in IMAs thus far 
include CD74 (the most common), SLC3A2, and VAMP2 
(14,15,18,19). IMAs also harbor, albeit at low frequencies, 
ERBB2 mutations, BRAF mutations, BRAF fusions, and 
NTRK1 fusions (14,15). Drugs selectively targeting these 
kinases may be useful for treating IMAs, particularly given 
the success of kinase inhibitors in the treatment of lung 
cancers with EGFR mutations or ALK rearrangements.
Maeda et al. and Snyder et al. reported that KRAS lung 
cancer mouse models with reduced expression of NKX2-1 
(also known as TTF-1) developed mucinous lung tumors 
mimicking human IMA (20,21). Recently, Hwang et al. 
found that frameshift or nonsense mutations in NKX2-1 
occurred in approximately 19% (4/21) of IMAs as 
determined via next-generation sequencing and Sanger 
sequencing (16). Owing to these mutations, the TTF-1 
protein was not expressed, which is a common finding in 
IMAs. INMAs, on the other hand, express wild-type NKX2-1, 
Figure 1 A representative photograph of an invasive mucinous 
adenocarcinoma (IMA) demonstrating goblet or columnar tumor 
cells with abundant intracytoplasmic mucin and basally located 
nuclei, characteristic of IMA. (Hematoxylin and eosin stain, 
magnification ×200).
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whose protein product (TTF-1) suppresses the expression 
of FOXA3, SPDEF, and HNF4A and, consequently, the 
expression of the mucin-related genes MUC5AC, MUC5B, 
and MUC3 (22). In IMAs, loss of TTF-1 expression owing 
to NKX2-1 mutation would de-repress the transcription of 
these downstream genes, thus accounting for the presence 
of HNF4α (11) and MUC5AC (9) in these tumors.
Primary IMAs are often indistinguishable from 
metastatic adenocarcinomas of the gastrointestinal or 
pancreatobiliary tract as both tumor types may have 
KRAS mutations and produce mucin (7). Differentiation is 
especially challenging if these tumors, in the lung or other 
primary sites, express CDX-2 and have the same type of 
KRAS mutation (7). Furthermore, recent RNA sequencing 
analysis of IMAs revealed a “mucinous signature” similar 
to that of gastrointestinal mucinous tumors (22). However, 
NKX2-1 mutations appear to be specific for pulmonary 
IMAs (16) and if present, may help differentiating a lung 
primary from metastasis from the other sites. 
Interestingly, IMAs rarely exhibit TP53 mutations, 
which may reflect the lower mutation burden of IMAs 
compared with that of INMAs (15). IMAs rarely express 
PD-L1 and predominantly occur in people who are not 
heavy smokers (18,22). In comparison, KRAS-mutated 
INMAs have a higher rate of T53 mutation and PD-L1 
expression and occur mainly in heavy smokers (23-25). 
Hence, IMAs and INMAs differ genetically in terms of 
mutation burden even in the presence of KRAS mutations. 
Thus far, comprehensive gene expression profiling of IMAs 
has fallen short, perhaps because of their lower prevalence 
than INMA. Furthermore, previous expression data did not 
consider histologic subtypes in detail. However, a recent 
study demonstrated that IMAs has distinct expression 
profiles through RNA sequencing. IMAs express VTCN1/
B7-H4 mRNA, whose protein product regulates an immune 
checkpoint and hence is a potential immunotherapy 
target, while they do not appreciably express PD-L1, as do 
INMAs (22). This finding may open new avenues of 
treatment using immune checkpoint inhibitors aimed at 
proteins other than PD-1/PD-L1.
Clinical features, prognostic significance, and 
response to treatments
IMAs tend to present with multicentric opacities or 
consolidation and multi-lobar and bilateral involvement, 
mimicking pneumonia (1,26). Interestingly, primary IMAs 
are frequently found in the lower lobes of the lungs (26). 
Survival data for IMA are limited owing to its low 
incidence and tend to be contradictory (15,27,28). Yoshizawa 
et al. classified IMAs as high-grade based on a relatively high 
recurrence rate (76% in 5 years) (27), although the data 
may lack definitive prognostic significance given the small 
number of IMAs and the study population limited to stage 
I tumors in their study. The high recurrence rate could 
be explained by microscopic skip lesions, a characteristic 
feature of IMA, which is relevant to the concept of spread 
through airspace (STAS) of tumor cells (29). STAS is a 
recently described concept defined as tumor cells within air 
spaces in the lung parenchyma beyond the edge of the main 
tumor (29). Besides the conventional concept of ‘invasion’ 
in lung cancer—infiltration of stroma, blood vessels, or 
pleura—STAS is a newly recognized pattern of invasion in 
lung cancer, based on its anatomical characteristics that lung 
Figure 2 Pie chart showing the percentages of invasive mucinous adenocarcinomas (n=162) that harbor the indicated driver genes [combined 
data from references (14) and (15) are shown].
ERBB2 1.23%
BRAF 1.85%
BRAF 1.23%
NTRK1 0.62%
ALK 1.85%
PIK3CA 0.62%
EGFR 0.62%
ERBB4 0.62%
Unknown 21.60%
Unknown 
21.60%
Mutation 
66.7%
Fusion
11.7%
KRAS 62.35%RET 0.62%
NRG1 6.79%
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is an air-filled organ with supporting alveolar structures. 
When STAS was present in the sub-anatomically resected 
lung, both locoregional and distant recurrence rates were 
significantly increased (29). As STAS contributes to patient 
prognosis, especially local recurrence, even in small early-
stage adenocarcinomas (29,30), the skip patterns of IMA 
may do likewise. In IMAs, it is hypothesized that tumor cells 
travel in the background of abundant alveolar mucin and 
become situated in the alveolar walls away from the primary 
lesion. In our previous study, however, the recurrence-
free survival rate did not differ significantly between IMAs 
and other tumors (15). Interestingly, all recurrences were 
limited to the lungs with no extrapulmonary metastases (15). 
Another study showed that even patients with IMA had 
longer recurrence-free survival than patients with INMA (28), 
and recurrences after surgical resection appear to be 
associated with the size of non-lepidic invasive pattern, and 
the presence of pleural and/or vascular invasion (31). These 
findings suggest that IMAs may not be aggressive tumors. 
In support, in a study of stage IV IMAs, overall survival (OS) 
was significantly better in untreated IMA patients than in 
untreated INMA patients (26). 
Patients with lung adenocarcinomas harboring EGFR 
mutations or ALK/ROS1 rearrangements qualify for 
targeted treatments with tyrosine kinase receptor inhibitors 
(TKIs). However, IMA patients are usually ineligible for 
such treatments, as well as for clinical trials of TKIs, owing 
to the rarity or absence of targetable mutations. Instead, 
most patients with advanced-stage IMAs receive non-TKI, 
platinum-based conventional chemotherapy (CTx), which, 
according to our previous study, does not improve OS 
relative to no treatment (26). Non-TKI CTx did, however, 
improve OS in INMA patients, although to a lesser extent 
than did TKI-based therapy in INMA patients with 
targetable mutation (26). These results indicate that IMA 
patients do not appreciably benefit from non-TKI CTx, and 
hence, new therapeutic approaches are required for IMAs of 
the lung.
Conclusions
Our rapidly evolving knowledge of the genetic and clinical 
characteristics of IMAs confirms the uniqueness of this 
disease among other primary lung adenocarcinomas. New 
findings regarding the targetable genetic alterations and 
clinical profiles of IMAs are anticipated to result in better 
patient management. Via comprehensive clinicopathologic 
and molecular analyses, IMAs will be more accurately 
diagnosed and more thoroughly investigated.
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